23 Oct 2015 07:00
Cyprotex PLC
("Cyprotex" or the "Company" or the "Group")
Trading update
Cyprotex PLC (AIM: CRX), the preclinical ADME-Tox services company, provides an update on revenue and profit guidance for the year to 31 December 2015.
Trading update
The financial performance of the Company for the first nine months of the year is ahead of expectations driven by continuing strong growth in UK revenues and whilst there still remain challenges as referred to in previous announcements, particularly in the US operations which still need some attention but which are much improved from earlier in the year, the Board expects that its full year revenues and EBITDA will exceed current market expectations.
For further information:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | ir@cyprotex.com www.cyprotex.com |
N+1 Singer (Nomad and broker to Cyprotex) | Tel: +44 (0)20 7496 3000 |
Shaun Dobson Jen Boorer
| shaun.dobson@n1singer.com jennifer.boorer@n1singer.com www.n1singer.com |
Notes to Editors:
Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1200 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling using PBPK, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com